Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
The med-tech company PolarCool AB (publ.) has entered into an agreement with the professional ice hockey team Manchester Storm in the British Elite Ice Hockey League (EIHL). The club becomes the third team in the league to use PolarCap® for the acute treatment of concussions.
With Manchester Storm as a new customer, PolarCool further expands its presence in the British top league, which consists of a total of ten teams from England, Northern Ireland, Scotland, and Wales. PolarCool already has agreements in place with Cardiff Devils and Sheffield Steelers for the use of PolarCap®.
PolarCool's CEO, Erik Andersson, comments:
-We are very pleased that Manchester Storm have chosen to provide PolarCap®. We are seeing increasing interest in the British league, and this agreement is an indication that our solution addresses a genuine need. We see strong potential for additional EIHL clubs to follow the clubs that now already provide PolarCap®.
PolarCool currently has a strong customer base within European professional ice hockey, with teams using PolarCap® in top leagues across Sweden, Germany, Switzerland, Finland, Austria, France, the Czech Republic, and Slovakia. Manchester Storm will use PolarCap® for the remainder of the season during an initial evaluation period, with the possibility of continuing into a two-year commercial agreement following the evaluation. Although individual agreements may have limited financial impact, this marks an important step in PolarCool's long-term growth strategy and its ambition to strengthen its position in the European market.
For more information
Erik Andersson - CEO PolarCool AB (publ.)
+46 - 73 860 57 00
E-mail: erik.andersson@polarcool.se
About PolarCool AB (publ.)
PolarCool AB (publ.) is a Swedish medical technology company focused on developing and marketing products in the sports medicine field. Its primary product, PolarCap®, is designed to reduce the impact of concussion through targeted brain cooling. PolarCool works with professional teams across Europe in rugby, football, and ice hockey and its shares are listed on Spotlight Stock Market.